US spends $4.3bn a year on cancer screening
An expert at the Center for Surgery and Public Health at Brigham and Women’s Hospital…
Category: Oncology
Low risk prostate cancer: active surveillance does not increase unfavourable outcomes, study finds
Active surveillance of men with prostate cancer with a low risk of metastasis is an…
Doctor is struck off for trying to sell unproven treatments to patient with advanced cancer
A doctor in private practice who tried to sell unproven treatments to a patient with…
Breast cancer: Inaction on inequalities has led to unequal progress, say experts
Despite tremendous advances in breast cancer research and treatment over the past three decades many…
Cancer: Fast tracked drugs often do not improve clinical outcomes, say researchers
Most cancer drugs granted accelerated approval in the US did not demonstrate benefit in overall…
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest
Pfizer spent more than four hours Thursday laying out its oncology program to investors. But…
NHS rolls out national gene testing to spot cancer risk in Jewish community
Jewish people in England are being invited to take part in a national gene testing…
STAT+: Insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM
New artificial intelligence technologies made headlines last year for their ability to do everything from…
NHS England’s “celebratory” cancer check announcement does not reflect reality, charities say
NHS England’s announcement highlighting record numbers of cancer checks does not reflect the “brutal” reality…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
Long term investment could avert 20 000 cancer deaths a year by 2040, says charity
The UK urgently requires sustained and ambitious investment in cancer care to reduce mortality and…
Working in the sun causes one in three non-melanoma skin cancer deaths, WHO warns
The World Health Organization has called on governments to ensure that outdoor workers are protected…
Clinicians raise concerns over pilot of blood test for multiple cancers
Cancer alliances across England are preparing to pilot the multi-cancer early detection (MCED) test Galleri—a…
Authors’ reply to Oke and Welch
We thank Oke and Welch for their response.1The aim of our study2 is to provide…
Breast cancer: conflating case fatality with mortality
While we agree with Taylor and colleagues that the prognosis for women with breast cancer…
Cancer charity questions NHS England’s claim that waiting times are improving
A UK cancer charity has challenged NHS England over its use of statistics, claiming that…
National Cancer Research Institute to close in “another blow” to UK research community
The National Cancer Research Institute (NCRI), a UK wide partnership between cancer research funders, has…
Harald zur Hausen: groundbreaking HPV researcher and vaccination advocate
bmj;381/jun20_13/p1421/FAF1fahausen160623.f1Credit: Thomas Lohnes/DDP/AFP/Getty ImagesIn 1842 an Italian physician in Florence observed that married women were…
Searching for answers: prostate screening in a stretched NHS
The UK National Screening Committee is due to review its advice on prostate cancer screening…
Beach nudity spreads skin cancer message
bmj;379/nov29_12/o2882/FAF1faDon ArnoldThousands of people posed naked on Bondi Beach in Sydney, Australia, at sunrise last…
Backlog for colonoscopy appointments could be cleared by raising test threshold, study suggests
Temporarily raising the threshold for the national bowel cancer screening programme could help clear the…
Quebec doctors’ letter forces government rethink on polluted cancer black spot
An open letter from 50 local physicians has brought promises of government action in an…
Chemotherapy delivery service by drone lifts off
bmj;378/jul12_12/o1709/FAF1faPatients with cancer in England will be the first in the world to benefit from…
Shortages of radiology and oncology staff putting cancer patients at risk, college warns
Patients in the UK with cancer are at risk from “devastating” effects of shortfalls of…
Russia’s war in Ukraine is killing cancer care in both countries
As the war in Ukraine unleashed chaos and upended millions of lives, many Ukrainians had…
Government has overseen “years of decline” in cancer and elective care, say MPs
The Department of Health and Social Care for England has presided over a sustained decline…
Oncologist with “cavalier attitude” to treatment is suspended for nine months after patients defend his practice
Justin Stebbing, an oncologist with a world reputation for cutting edge treatment and research, has…
Government promises 40 new diagnostic centres to tackle backlog
The government has pledged £350m (€410m; $470m) to set up 40 new “one-stop-shops for checks,…
Cancer outcomes—what’s stalling progress in England?
England will miss the 2028 cancer targets set out in the NHS long term plan…
STAT+: Tempus unveils prototype cube that talks back to oncologists
Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube,…
Trial to extend breast cancer screening won’t resume randomisation after pandemic
A major UK breast cancer screening trial that was set up to determine whether extending…
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone…
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
Dateline City: KENILWORTH, N.J. First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA…
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab…
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Dateline City: KENILWORTH, N.J. Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six…
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH,…
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Dateline City: KENILWORTH, N.J. First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine…
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at…
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)
Dateline City: KENILWORTH, N.J. In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved…
US cancer centre leaders secretly worked for China, internal report finds
Six researchers who resigned last month from Florida’s Moffitt Cancer Center admitted to opening secret…
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Dateline City: KENILWORTH, N.J. Submission Based on PROfound, the First Phase 3 Trial Evaluating a…